Shares of Mirum Pharmaceuticals rose after its Livmarli drug, also called maralixibat, met the primary endpoint in a recent trial for the treatment of cholestatic pruritus in certain patients with liver diseases.
The stock rose 3.3% to $61.05 in premarket trading on Monday. At Friday's market close, shares were up 8.9% year to date.
In the Phase 3 study, which evaluated maralixibat in patients aged six months or older with ultra-rare cholestatic liver diseases, the proposed treatment demonstrated a statistically significant improvement in pruritus compared with placebo in pediatric patients, the company said.
Maralixibat also resulted in a 70% reduction from baseline in serum bile acids, compared with 3.5% for placebo.
Chief Medical Officer Rob Myers said those two measures reinforce the potential for maralixibat to help with pruritus, which he said is a significant burden faced by patients with ultra-rare cholestatic liver diseases.
The company said it plans to submit a supplemental new drug application in the U.S. in the first half of 2027 based on the study results.
Comments